Jan Näslund

Title: Jan Näslund: Innovator in Amyloid Research

Introduction

Jan Näslund is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of amyloid research, particularly in the development of compounds that inhibit the polymerization of amyloid beta peptide. His work is crucial for advancing our understanding of amyloid-related diseases.

Latest Patents

Jan Näslund holds a patent for a peptide that binds the KLVFF-sequence of amyloid beta. This invention relates to compounds that are of interest for inhibiting the polymerization of amyloid beta peptide. These compounds serve as model substances for the synthesis of amyloid beta peptide-ligands and as tools for identifying other organic compounds with similar functional properties. Additionally, they can be used as ligands for the detection of amyloid deposits through techniques such as positron emission tomography (PET).

Career Highlights

Jan is associated with Karolinska Innovations AB, where he continues to contribute to innovative research in the biomedical field. His work has implications for the diagnosis and treatment of diseases associated with amyloid deposits, such as Alzheimer's disease.

Collaborations

Jan has collaborated with notable colleagues, including Christer Nordstedt and Lars Terenius. These partnerships have enhanced the scope and impact of his research in amyloid-related studies.

Conclusion

Jan Näslund's innovative work in the field of amyloid research highlights the importance of developing new compounds for medical applications. His contributions are paving the way for advancements in the understanding and treatment of amyloid-related diseases.